American Funds®

  • Forms
  • MY ACCOUNTS
  • INVESTMENTS
  • INSIGHTS
  • PRODUCTS
  • PLANNING
  • SERVICE & SUPPORT

GROWTH & INCOME FUNDS

®

All Holdings

BACK TO FUND'S DETAIL PAGE
No holdings data is available at this time.
213 Total Holdings:
As of 12/31/15 (updated quarterly, upon availability).
All Holdings: 1 - 15 of 213
Asset Type
Verizon Communications Inc. Equity 31,241,814 $1,443,996,643.00 4.15%
Amgen Inc. Equity 7,764,272 $1,260,374,274.00 3.62%
AbbVie Inc. Equity 17,325,800 $1,026,380,392.00 2.95%
Texas Instruments Inc. Equity 18,311,644 $1,003,661,208.00 2.88%
Microsoft Corp. Equity 15,925,607 $883,552,676.00 2.54%
Home Depot, Inc. Equity 5,384,352 $712,080,552.00 2.05%
Coca-Cola Co. Equity 14,139,900 $607,450,104.00 1.75%
Procter & Gamble Co. Equity 7,473,400 $593,462,694.00 1.71%
General Electric Co. Equity 18,986,585 $591,432,123.00 1.7%
AT&T Inc. Equity 16,866,000 $580,359,060.00 1.67%
Lockheed Martin Corp. Equity 2,548,460 $553,398,089.00 1.59%
Sempra Energy Equity 5,396,653 $507,339,349.00 1.46%
Boeing Co. Equity 3,095,600 $447,592,804.00 1.29%
Medtronic PLC Equity 5,735,500 $441,174,660.00 1.27%
Waste Management, Inc. Equity 7,878,100 $420,454,197.00 1.21%
All Holdings: 1 - 15 of 213

Investments are not FDIC-insured, nor are they deposits of or guaranteed by a bank or any other entity, so they may lose value.

Investors should carefully consider investment objectives, risks, charges and expenses. This and other important information is contained in the fund prospectuses and summary prospectuses, which can be obtained from a financial professional and should be read carefully before investing.

Bond ratings, which typically range from AAA/Aaa (highest) to D (lowest), are assigned by credit rating agencies such as Standard & Poor's, Moody's and/or Fitch, as an indication of an issuer's creditworthiness.

  1. Excludes certain securities in initial period of acquisition.

For more information about the risks associated with each fund, go to its detailed fund information page or read the prospectus.